DaltonTx Launches AI-Powered Drug Discovery Platform, Signs Sygnature Discovery as First Client
核心洞察
DaltonTx (搜索) has officially launched Dalton, an AI-powered drug discovery platform that unifies data, models, and experimental results into a continuous learning engine for both small-molecule and biologic medicines.
Sygnature Discovery (搜索), a leading integrated drug discovery CRO, has signed on as the first client and is conducting a retrospective evaluation using a legacy oncology program currently in Phase I.
The platform differentiates itself through data privacy, siloing customer data and AI models on a per-program basis to ensure proprietary information is not used to train models for other projects.
A new contender has entered the rapidly expanding AI-driven drug discovery arena. DaltonTx (搜索), a London-based startup founded by former scientists from AstraZeneca, Exscientia, and the University of Oxford, has officially launched its flagship platform, Dalton, and simultaneously announced that contract research organisation (CRO) Sygnature Discovery (搜索) has signed on as its first client.
The Dalton platform is designed to serve as an intelligence backbone for modern drug discovery, integrating agentic AI, human expertise, and experimental data into a single continuous learning engine. It supports the full drug discovery process—from raw data and model training to molecular design, synthesis, and decision-making—across both small-molecule and biologic programs.
"We believe that the organisations capturing the most value from AI will be those that connect their teams, tools and data into systems that improve real-world discovery decisions," said Garry Pairaudeau, DaltonTx (搜索)'s co-founder and chief executive, who spent 20 years in AstraZeneca's R&D operations and served as chief technology officer at Exscientia before its merger with Recursion in 2024.
A Platform Built on Organisational Memory
Dalton links molecules, assays, models, experimental outcomes, project context, and human decisions into a single learning system. Critically, it captures not only what happened, but also why a particular path was chosen. Over time, this builds organisational memory across discovery programmes, helping teams understand which approaches worked, which did not, and how they can make better decisions in the future.
The platform supports every step of the design-make-test-analyse (DMTA) cycle by integrating experimental data, predictive models, physics-based methods, and AI agents into conversational workflows. Scientists can use Dalton to plan analyses, orchestrate computational tools, compare different modelling approaches, update models as new data is generated, and surface suggestions on what to do next.
"Our Dalton drug discovery platform unifies data, models, and experimental results to capture what worked, what failed and why, with full context, so judgement compounds over time," Pairaudeau added, emphasising that the role of Dalton is "supercharging" rather than replacing human expertise.
Data Privacy as a Key Differentiator
In an environment where proprietary data use is a growing industry concern, DaltonTx (搜索) has made data privacy a cornerstone of its offering. Customer data and AI models are compartmentalised on a per-program basis, ensuring that no project's information is used to train models supporting other projects. Sygnature Discovery (搜索) confirmed this approach, noting that customer information remains siloed and is not used to train models elsewhere.
Sygnature Discovery (搜索) Partnership and Retrospective Validation
Sygnature Discovery (搜索), which employs over 700 scientists across Europe and North America and has contributed to more than 60 advanced candidates and over 200 patents filed, will integrate Dalton into its existing computational and medicinal chemistry toolkit. This stack already includes proprietary and third-party technologies such as SygDesign, BullFrog AI, and Iktos.
"AI in drug discovery continues to evolve rapidly, but we believe the future lies in combining the power of machine learning with the expertise and intuition of experienced scientists," said Simon Hirst, CEO of Sygnature Discovery (搜索). "We are excited to be working with DaltonTx (搜索) and see how they can help scientists make better-informed decisions earlier in the discovery process, so that we can reduce the number of compounds synthesised and tested, shorten DMTA cycles and accelerate progression toward candidate selection."
As part of the collaboration, Sygnature Discovery (搜索) is conducting a retrospective evaluation using a legacy oncology programme focused on a small molecule clinical candidate now in Phase I development. The analysis is assessing whether the Dalton platform could have enabled the team to reach candidate selection more efficiently through improved decision-making and reduced synthesis burden. Sygnature Discovery intends to extend validation of the Dalton platform into live customer programmes as opportunities arise.
Competitive Landscape
DaltonTx (搜索) enters an increasingly crowded market for AI-powered drug discovery toolkits, competing with established players such as Recursion Pharma (搜索), Insilico Medicine (搜索), and Schrödinger (搜索), as well as technology heavyweights including NVIDIA, Alphabet's Isomorphic Labs, OpenAI, and Amazon. The company believes its strong biopharma heritage and focus on enablement—rather than building an in-house pipeline of therapies—could help it carve out a meaningful share of the market.
"The next phase of AI in drug discovery is about impact," said Pairaudeau. "We are proud to be working with such a respected industry partner as Sygnature Discovery (搜索), and it is a great endorsement of the tangible outcomes that Dalton can translate into measurable value."